Industrialization base
The total construction area of the industrialization base of HPV vaccines is more than 100,000 square meters. After the first phase of the project is completed, the annual production capacity of 5 million doses of 9-valent HPV vaccines will be reached.
The total investment of the COVID-19 vaccine project is not less than CNY 500 million, the construction area is about 17,000 square meters, and the annual production capacity will reach 100 million doses.
All categories

Industrialization project of recombinant COVID-19 vaccine



On November 23, 2020, the recombinant COVID-19 vaccine industrialization project of RecBio was started. Since May of this year, with great care and support of the leaders of the Taizhou Pharmaceutical Hi-tech Industrial Development Zone and China Medical City, Jiangsu CDC and Jiangsu RecBio formed a joint research team for the COVID-19 vaccine led by Professor Zhu Fengcai. Relying on the world-class protein engineering and new adjuvant innovative R & D technology platform, we have made every effort to develop innovative COVID-19 vaccines significantly superior to those of other technical routes in terms of safety, efficacy and accessibility, providing the optimal vaccine solution for curbing the pandemic worldwide


The total investment of the project is not less than RMB 500 million, and the designed construction area is 18,000 square meters. It is the largest COVID-19 vaccine production base constructed at one time in China, which mainly includes the construction of COVID-19 vaccine stock solution production workshop, sub-packaging workshop, new adjuvant workshop, quality inspection center, and other auxiliary facilities. The project is expected to be completed in early 2021, with an annual production capacity of 100 million doses, and the expanded production capacity of 200 million doses is reserved in the workshop. In the second half of 2021, an annual production capacity of 300 million doses will be reached. The recombinant COVID-19 vaccine of RecBio is expected to enter phase I clinical trial in January 2021 and phase III clinical trial in April 2021, and be launched in the market in the second half of 2021.

  • TOP   

Contact Us


Time of issue:2022-03-29 08:59:20

Jiangsu Recbio Technology Co., Ltd.

Media Inquiry:

Investor Inquiry:


Address: Vaccine Engineering Center, China Medical City, Taizhou

Copyright © 2020 Jiangsu Rec-Biotechnology Co., Ltd.  All rights reserved.      苏ICP备19043567号-1